Inovio Pharmaceuticals (INO) Other financing activities (2010 - 2025)
Inovio Pharmaceuticals (INO) posted Other financing activities of -$751134.0 for Q4 2025, down 199.87% sequentially from $752134.0 in Q3 2025, and down 1009.91% YoY from $82550.0 in Q4 2024.
Inovio Pharmaceuticals (INO) Other financing activities (2010 - 2025) Analysis & Trends
Inovio Pharmaceuticals has reported Other financing activities for 13 years, with the latest figure at -$751134.0 in Q4 2025.
- Quarterly Other financing activities fell 1009.91% year-over-year to -$751134.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$16.1 million (changed 0.01% YoY) and the FY2025 annual result came in at $1000.0, changed N/A from the prior year.
- Other financing activities eased to -$751134.0 in Q4 2025 per INO's latest filing, from $752134.0 in the prior quarter.
- Over five years, Other financing activities peaked at $3.5 million in Q2 2021 and troughed at -$16.1 million in Q3 2024.
- A 4-year average of -$1.3 million and a median of $88656.0 in 2022 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 104.68% in 2025, down 1009.91% in 2025.
- Over 4 years, Other financing activities stood at -$6.4 million in 2021, then jumped by 95.58% to -$283022.0 in 2022, then soared by 76.09% to -$67675.0 in 2024, then slumped by 1009.91% to -$751134.0 in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered -$751134.0, $752134.0, and -$67675.0 for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -751,134.00 |
| Dec 31, 2025 | -751,134.00 |
| Sep 30, 2025 | 752,134.00 |
| Sep 30, 2025 | 752,134.00 |
| Dec 31, 2024 | -67,675.00 |
| Dec 31, 2024 | -67,675.00 |
| Sep 30, 2024 | -16.08 Mn |
| Sep 30, 2024 | -16.08 Mn |
| Dec 31, 2022 | -283,022.00 |
| Dec 31, 2022 | -283,022.00 |
| Sep 30, 2022 | 93,500.00 |
| Sep 30, 2022 | 93,500.00 |
| Jun 30, 2022 | 105,710.00 |
| Jun 30, 2022 | 105,710.00 |
| Mar 31, 2022 | 83,812.00 |
| Mar 31, 2022 | 83,812.00 |
| Dec 31, 2021 | -6.41 Mn |
| Dec 31, 2021 | -6.41 Mn |
| Sep 30, 2021 | 255,408.00 |
| Sep 30, 2021 | 255,408.00 |